Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Advanced Tech.
8 min read
The Multifunctional Novel Products of DNA Recombinant Technology: Fusion Protein
11 October 2023
Fusion protein technology is a purposeful gene fusion and protein expression method to obtain large amounts of standard fusion proteins.
Drug Insights
4 min read
Revefenacin Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs, Mechanisms of Action, and Drug Target
11 October 2023
This article summarized the latest R&D progress of Revefenacin, the Mechanism of Action for Revefenacin, and the drug target R&D trends for Revefenacin.
Latest Hotspot
3 min read
Structure Therapeutics reports outcomes from the Phase 1b clinical study of GSBR-1290
11 October 2023
Structure Therapeutics has revealed encouraging results from its Phase 1b incremental dose study of its exclusive oral GLP-1 receptor agonist, GSBR-1290, in overweight or obese individuals.
Drug Insights
4 min read
Unleashing the Power of Risedronate sodium: A Comprehensive Review on R&D Breakthroughs, Action Mechanisms, and Drug Target
11 October 2023
This article summarized the latest R&D progress of Risedronate sodium, the Mechanism of Action for Risedronate sodium, and the drug target R&D trends for Risedronate sodium.
Advanced Tech.
6 min read
AstraZeneca reports Phase I clinical trial of inhaled JAK1 inhibitor AZD4604
11 October 2023
Recently, AstraZeneca published in JMC, detailing the development of the inhaled JAK1 inhibitor AZD4604.
Drug Insights
4 min read
A Comprehensive Review of Roxadustat's R&D Innovations and Drug Target Mechanism
10 October 2023
This article summarized the latest R&D progress of Roxadustat, the Mechanism of Action for Roxadustat, and the drug target R&D trends for Roxadustat.
Latest Hotspot
3 min read
Amicus Therapeutics Declares FDA Sanction and Introduction of Novel Therapy for Pompe Disease
10 October 2023
Amicus Therapeutics has confirmed that the U.S. FDA has given the green light to Pombiliti™ (cipaglucosidase alfa-atga) + Opfolda™ (miglustat) 65mg capsules.
Drug Insights
4 min read
Pharmaceutical Insights: Rufinamide's R&D Progress and its Mechanism of Action on Drug Target
10 October 2023
This article summarized the latest R&D progress of Rufinamide, the Mechanism of Action for Rufinamide, and the drug target R&D trends for Rufinamide.
Valuable Targets
5 min read
Advances in Clinical Research on Leukotriene Receptor Antagonist
10 October 2023
CysLT, or cysteinyl leukotrienes, are inflammatory mediators produced by various cells in the human body, including mast cells, eosinophils, and macrophages.
Drug Insights
4 min read
Exploring Selinexor's Revolutionary R&D Successes and its Mechanism of Action on Drug Target
10 October 2023
This article summarized the latest R&D progress of Selinexor, the Mechanism of Action for Selinexor, and the drug target R&D trends for Selinexor.
Latest Hotspot
3 min read
IASO Bio showcases Updated Long-Term Follow-Up information for BCMA CAR-T FUCASO®
10 October 2023
These studies focused on the outcomes of the Phase 1b/2 study carried out on patients who had relapsed/refractory multiple myeloma and were undergoing treatment with Equecabtagene Autoleucel.
Drug Insights
4 min read
Decoding Terbinafine hydrochloride: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
10 October 2023
This article summarized the latest R&D progress of Terbinafine hydrochloride, the Mechanism of Action for Terbinafine hydrochloride, and the drug target R&D trends for Terbinafine hydrochloride.